A Phase I clinical trial in patients with glioblastoma using the combination of Ad-RTS-IL-12 (INXN-2001) and veledimex and a selected checkpoint inhibitor

Trial Profile

A Phase I clinical trial in patients with glioblastoma using the combination of Ad-RTS-IL-12 (INXN-2001) and veledimex and a selected checkpoint inhibitor

Planning
Phase of Trial: Phase I

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs INXN 2001 (Primary) ; Veledimex (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Sponsors ZIOPHARM Oncology
  • Most Recent Events

    • 16 Feb 2017 According to a ZIOPHARM Oncology media release, the company expects to initiate this study during the first half of 2017.
    • 01 Mar 2016 New trial record
    • 24 Feb 2016 The company expects to begin this trial in 2016, according to a Ziopharm media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top